Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 2
2013 3
2014 2
2015 2
2016 1
2017 8
2018 6
2019 9
2020 12
2021 26
2022 30
2023 27
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
[Innovative therapies for treatment of invasive fungal diseases].
Mellinghoff SC, Cornely OA, Mammadova P, Sprute R, Stemler J. Mellinghoff SC, et al. Dtsch Med Wochenschr. 2024 May;149(10):560-568. doi: 10.1055/a-2132-9240. Epub 2024 Apr 24. Dtsch Med Wochenschr. 2024. PMID: 38657595 Review. German.
This review aims to give a comprehensive overview of emerging treatment strategies.Novel drugs in development are Ibrexafungerp, an orally available triterpenoid inhibiting glucan synthesis, and Rezafungin representing the echinocandins with extended half-life and improved …
This review aims to give a comprehensive overview of emerging treatment strategies.Novel drugs in development are Ibrexafungerp, an o …
Biosynthesis of Enfumafungin-type Antibiotic Reveals an Unusual Enzymatic Fusion Pattern and Unprecedented C-C Bond Cleavage.
Cao ZQ, Wang GQ, Luo R, Gao YH, Lv JM, Qin SY, Chen GD, Awakawa T, Bao XF, Mei QH, Yao XS, Hu D, Abe I, Gao H. Cao ZQ, et al. J Am Chem Soc. 2024 Apr 23. doi: 10.1021/jacs.4c02415. Online ahead of print. J Am Chem Soc. 2024. PMID: 38654452
These compounds exhibit significant antifungal properties with ibrexafungerp, a semisynthetic derivative of enfumafungin, recently gaining FDA's approval as the first oral antifungal drug for treating invasive vulvar candidiasis. ...
These compounds exhibit significant antifungal properties with ibrexafungerp, a semisynthetic derivative of enfumafungin, recently ga …
Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials.
He R, Lin F, Yu B, Huang L. He R, et al. Heliyon. 2024 Apr 5;10(8):e28776. doi: 10.1016/j.heliyon.2024.e28776. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38628772 Free PMC article.
BACKGROUND: This study aims to evaluate the efficacy and safety associated with ibrexafungerp in the treatment of vulvovaginal candidiasis infection patients. ...CONCLUSION: In summary, the use of ibrexafungerp was linked to superior clinical cure ratio, and mycolog …
BACKGROUND: This study aims to evaluate the efficacy and safety associated with ibrexafungerp in the treatment of vulvovaginal candid …
Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus.
Dos Reis TF, Diehl C, Pinzan CF, de Castro PA, Goldman GH. Dos Reis TF, et al. bioRxiv [Preprint]. 2024 Apr 5:2024.04.05.588305. doi: 10.1101/2024.04.05.588305. bioRxiv. 2024. PMID: 38617338 Free PMC article. Preprint.
Here, we show that the host defense peptide mimetic, brilacidin (BRI) can potentiate ibrexafungerp (IBX) against clinical isolates of A. fumigatus. CAS-resistant strains with mutations in fks1 that encodes the 1,3-beta-D-glucan synthase are not IBX-resistant and BRI+IBX ca …
Here, we show that the host defense peptide mimetic, brilacidin (BRI) can potentiate ibrexafungerp (IBX) against clinical isolates of …
Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study.
Wang X, Wang W, Li J, An R, Chen L, Lin J, Xu D, Qiu J, Song W, Patiman M, Ruan H, Wang G, Xue F, Wang X, Luo X, Ruan Q, Shi L, Zhang C, Hu L, Wang S, Shi H, Wang X, Zhang S, Li Y, Lu J, Wang B, Xu H, Ye H, Zhang B, Zhang C, Qian S, Wu Q, Jia W, Li C, Liao Q. Wang X, et al. Infection. 2024 Apr 3. doi: 10.1007/s15010-024-02233-w. Online ahead of print. Infection. 2024. PMID: 38568411
PURPOSE: To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC). ...Ibrexafungerp was generally well tolerated. Adverse events were primarily gastrointestinal and were mainly mild i …
PURPOSE: To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal ca …
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Gebremariam T, et al. Antimicrob Agents Chemother. 2024 Apr 1:e0154523. doi: 10.1128/aac.01545-23. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 38557112
We evaluated the in vivo efficacy of ibrexafungerp against pulmonary mucormycosis using an established murine model. Neutropenic mice were intratracheally infected with either Rhizopus delemar or Mucor circinelloides. Treatment with placebo (diluent control), ibrexafung …
We evaluated the in vivo efficacy of ibrexafungerp against pulmonary mucormycosis using an established murine model. Neutropenic mice …
New treatment options for critically important WHO fungal priority pathogens.
Kriegl L, Egger M, Boyer J, Hoenigl M, Krause R. Kriegl L, et al. Clin Microbiol Infect. 2024 Mar 9:S1198-743X(24)00118-6. doi: 10.1016/j.cmi.2024.03.006. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38461942 Free article. Review.
Ibrexafungerp, fosmanogepix, and rezafungin have additionally been granted orphan drug status by the European Medicines Agency in Europe (ibrexafungerp-November 2021, fosmanogepix-July 2022, and rezafungin-January 2024). IMPLICATIONS: Although the limited number of …
Ibrexafungerp, fosmanogepix, and rezafungin have additionally been granted orphan drug status by the European Medicines Agency in Eur …
Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy: Description of azole-resistance profiles associated with the Y132F ERG11p substitution.
Mesquida A, Alcoceba E, Padilla E, Ramírez A, Merino P, González-Romo F, De Carolis E, Sanguinetti M, Mantecón-Vallejo MLÁ, Muñoz-Algarra M, Durán-Valle T, Pérez-Ayala A, Gómez-García-de-la-Pedrosa E, Del Carmen Martínez-Jiménez M, Sánchez-Castellano MÁ, Quiles-Melero I, Cuétara MS, Sánchez-García A, Muñoz P, Escribano P, Guinea J; CANDIMAD study group. Mesquida A, et al. Mycoses. 2024 Mar;67(3):e13706. doi: 10.1111/myc.13706. Mycoses. 2024. PMID: 38438313
Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp susceptibility. RESULTS: Of the 53 genotypes found, 49 harboured the Y132F substitution, five of which were dominating city-specific genotypes inv …
Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp suscep …
Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective.
Hsu AJ, Hanisch BR, Fisher BT, Huppler AR. Hsu AJ, et al. J Pediatric Infect Dis Soc. 2024 Feb 28;13(Supplement_1):S68-S79. doi: 10.1093/jpids/piad115. J Pediatric Infect Dis Soc. 2024. PMID: 38417087 Review.
The overarching goal of this review is to discuss the mechanisms of action, spectrum of activity, stage of development, and pediatric-specific data for the following agents: encochleated amphotericin B deoxycholate, fosmanogepix, ibrexafungerp, isavuconazole, olorofim, ope …
The overarching goal of this review is to discuss the mechanisms of action, spectrum of activity, stage of development, and pediatric-specif …
130 results